PD-1/PD-L1 Inhibitor

About PeptiDream

PeptiDream's mission is to revolutionize drug discovery by developing macrocyclic peptides as a new therapeutic modality to address undruggable targets. The company has achieved remarkable success through its proprietary PDPS technology, securing high-value partnerships with nearly every major global pharmaceutical firm. Its strategy combines a capital-efficient platform business with the advancement of a proprietary pipeline, particularly in oncology and infectious diseases. This dual approach has generated significant revenue and driven its valuation to over $150 billion, positioning it as a dominant force in the peptide therapeutics space.

Therapeutic Areas

Other Various Solid Tumors Drugs